Free Trial

Solid Biosciences (SLDB) 10K Form and Latest SEC Filings 2026

Solid Biosciences logo
$7.63 +0.25 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$7.72 +0.09 (+1.11%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Solid Biosciences SEC Filings & Recent Activity

Solid Biosciences (NASDAQ:SLDB) has submitted 526+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Solid Biosciences's financial statements. The most recent filing was a Form 10-Q submitted on May 12, 2026.

Form 4
Solid Biosciences Inc. Reports Ownership Change on Apr. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Solid Biosciences Files Current Report on Apr. 10, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Solid Biosciences Files Quarterly Report on May. 12, 2026

The 10-Q contains Solid Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Solid Biosciences SEC Filing History

Browse Solid Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/12/2026 3:02 PM
Solid Biosciences (1707502) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2026 8:42 AM
Invus Global Management, LLC (2005369) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G/A
04/27/2026 3:12 PM
BlackRock, Inc. (2012383) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G/A
04/23/2026 3:12 PM
Solid Biosciences (1707502) Filer
Form ARS
04/23/2026 3:03 PM
Solid Biosciences (1707502) Filer
Form DEF 14A
04/21/2026 3:05 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:05 PM
Solid Biosciences (1707502) Issuer
Tan Kevin (1884056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:05 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:05 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:05 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:05 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 3:09 PM
Solid Biosciences (1707502) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2026 3:10 PM
Solid Biosciences (1707502) Filer
Form PRE 14A
03/31/2026 11:15 PM
Solid Biosciences (1707502) Filer
Form EFFECT
03/31/2026 11:15 PM
Solid Biosciences (1707502) Filer
Form EFFECT
03/19/2026 4:03 PM
Solid Biosciences (1707502) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/19/2026 4:04 PM
Solid Biosciences (1707502) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/19/2026 3:10 PM
Solid Biosciences (1707502) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/19/2026 3:01 PM
Solid Biosciences (1707502) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/17/2026 5:50 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13D/A
03/11/2026 3:00 PM
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (1249675) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 3:00 PM
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13D/A
03/10/2026 4:00 PM
BCLS SB Investco, LP (1728056) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13D/A
03/10/2026 3:38 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13D/A
03/06/2026 3:36 PM
Solid Biosciences (1707502) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/18/2026 8:25 PM
Solid Biosciences (1707502) Issuer
Tan Kevin (1884056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:28 PM
Solid Biosciences (1707502) Subject
Tan Kevin (1884056) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:28 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:30 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:31 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:31 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:31 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:32 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:32 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:33 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:34 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 8:35 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:35 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:38 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2026 8:09 AM
Adage Capital Management, L.P. (1535978) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G/A
02/06/2026 4:56 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
02/06/2026 4:57 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 4:59 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 5:00 PM
Solid Biosciences (1707502) Issuer
Tan Kevin (1884056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 5:01 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 5:01 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 5:05 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 6:37 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:40 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:42 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:44 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:45 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:46 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2026 6:48 PM
Solid Biosciences (1707502) Subject
Tan Kevin (1884056) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:15 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 7:16 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 7:18 PM
Solid Biosciences (1707502) Issuer
Tan Kevin (1884056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 6:59 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:01 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:03 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:04 PM
Solid Biosciences (1707502) Subject
Tan Kevin (1884056) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:05 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:07 PM
Hanrahan Jessie (1954826) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 7:07 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 7:09 PM
Herzich Paul (1954991) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 7:12 PM
Howton David T (1529297) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 7:14 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 4:00 PM
Solid Biosciences (1707502) Subject
Tan Kevin (1884056) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2026 4:02 PM
Solid Biosciences (1707502) Issuer
Tan Kevin (1884056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:05 PM
SMITH IAN F (1197032) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 5:52 PM
Ganot Ilan (1727460) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 4:07 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 8:07 AM
Adage Capital Management, L.P. (1535978) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G/A
11/03/2025 4:22 PM
Solid Biosciences (1707502) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/03/2025 4:15 PM
Solid Biosciences (1707502) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/21/2025 3:05 PM
Brooks Gabriel (1997809) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2025 3:05 PM
SMITH IAN F (1197032) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 3:10 PM
Cumbo Alexander (1685994) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 5:06 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13D/A
08/14/2025 4:07 PM
Commodore Capital LP (1831942) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G/A
07/17/2025 7:12 PM
BlackRock, Inc. (2012383) Filed by
Solid Biosciences (1707502) Subject
Form SCHEDULE 13G
07/08/2025 7:04 PM
SMITH IAN F (1197032) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 4:05 PM
EDELMAN JOSEPH (1164426) Reporting
PERCEPTIVE ADVISORS LLC (1224962) Reporting
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (1249675) Reporting
Solid Biosciences (1707502) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 4:06 PM
Solid Biosciences (1707502) Issuer
Stone Adam Leo (1727440) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 3:21 PM
Solid Biosciences (1707502) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2025 11:15 PM
Solid Biosciences (1707502) Filer
Form EFFECT
(Data available from 1/1/2016 forward)

Solid Biosciences SEC Filings - Frequently Asked Questions

Solid Biosciences (SLDB) has submitted 526+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Solid Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Solid Biosciences's financial statements page.

The most recent filing was a Form 10-Q submitted on May 12, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SLDB) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners